Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03119428
Recruitment Status : Terminated (Sponsor decision)
First Posted : April 18, 2017
Last Update Posted : August 11, 2020
Sponsor:
Information provided by (Responsible Party):
Mereo BioPharma ( OncoMed Pharmaceuticals, Inc. )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of OMP-31M32 as a single agent or in combination with nivolumab. OMP-313M32 is an experimental anti-TIGIT antibody that was developed to block TIGIT from binding PVR allowing the body's T-cells to destroy cancer cells.

Condition or disease Intervention/treatment Phase
Locally Advanced Cancer Metastatic Cancer Drug: OMP-313M32 Drug: Nivolumab Phase 1

Detailed Description:
This is an open-label, Phase 1a/b dose escalation study of OMP-31M32 administered as a single agent or in combination with nivolumab to evaluate the safety, tolerability pharmacokinetics, and pharmacodynamics in patients with locally advanced or metastatic solid tumors. This study consists of a screening period, a treatment period and a post-treatment follow-up period in which patients will be followed for survival for up to 2 years. Subjects will be enrolled in two stages in the Phase 1a (dose escalation and expansion) and one stage in the Phase 1b (dose escalation).
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent or in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Actual Study Start Date : May 2, 2017
Actual Primary Completion Date : May 15, 2019
Actual Study Completion Date : May 15, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Nivolumab

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: OMP-313M32
Intravenous (in the vein) infusions of OMP-313M32 as a single agent
 Drug: OMP-313M32
OMP-313M32 is a monoclonal antibody which binds to the human TIGIT receptor on T cells.
Other Name: Anti-TIGIT monoclonal antibody
Experimental: OMP-313M32 and Nivolumab
Intravenous (in the vein) infusions of OMP-313M32 in combination with nivolumab
 Drug: OMP-313M32
OMP-313M32 is a monoclonal antibody which binds to the human TIGIT receptor on T cells.
Other Name: Anti-TIGIT monoclonal antibody

Drug: Nivolumab
Human IgG4 anti-PD-1 monoclonal antibody
Other Name: Opdivo


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Incidence of dose limiting toxicities (DLTs) [ Time Frame: Subjects will be assessed for DLTs through the end of the first cycle (Days 1-29) ]
    The Maximum tolerated dose (MTD) or maximum administered dose (MAD) will be determined in patients treated with OMP-313M32 in combination with nivolumab

  2. Incidence of treatment emergent adverse events [ Time Frame: up to approximately 2 years ]
    Percentage of patients with adverse events


Secondary Outcome Measures :
  1. Pharmacokinetic Outcome Measures (AUC) - Phase 1a [ Time Frame: 1st dose and 4th dose: pre-dose, post-infusion, and 1, 3, 7 and 10 days. All other doses: pre-dose, 15 minutes and 7 days post-infusion. PK sample will be taken at treatment termination and every 4 wks for 12 wks. ]
    Area under the plasma concentration versus time curve (AUC) will be evaluated

  2. Pharmacokinetic Outcome Measures (AUC) - Phase 1b [ Time Frame: 1st dose and 4th dose: pre-dose and 15 minutes post-infusion. All other doses: pre-dose. PK sample will be taken at treatment termination and every 4 wks for 12 wks. ]
    Area under the plasma concentration versus time curve (AUC) will be evaluated

  3. Pharmacokinetic Outcome Measures (T1/2) - Phase 1a [ Time Frame: 1st dose and 4th dose: pre-dose, post-infusion, and 1, 3, 7 and 10 days. All other doses: pre-dose, 15 minutes and 7 days post-infusion. PK sample will be taken at treatment termination and every 4 wks for 12 wks. ]
    The half life (T1/2) of OMP-313M32 will be assessed

  4. Pharmacokinetic Outcome Measures (T1/2) - Phase 1b [ Time Frame: 1st dose and 4th dose: pre-dose and 15 minutes post-infusion. All other doses, pre-dose.PK sample will be taken at treatment termination and every 4 wks for 12 wks. ]
    The half life (T1/2) of OMP-313M32 will be assessed

  5. Immunogenicity of OMP-313M32 [ Time Frame: up to approximately 2 years ]
    Percentage of patients with anti-OMP-313M32 antibodies assessed

  6. Objective Response [ Time Frame: up to approximately 2 years ]
    Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)

  7. Progression-free survival [ Time Frame: approximately 2 years ]
    Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologic documentation of locally advanced, recurrent or metastatic solid malignancy that has progressed and standard therapy has been ineffective or intolerable. Phase 1b subjects must also have experienced disease progression after treatment with an anti PD-1 or PDL-1 agent.
  2. Ability to understand the willingness and to sign a written informed consent document
  3. Age >/= 18 years
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  5. Life expectancy >/=12 weeks
  6. Measurable disease per response evaluation criteria in solid tumors.
  7. Adequate hematologic and organ function
  8. For women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception from study entry through at least 6 months after the termination visit.

Exclusion Criteria:

  1. Anti-cancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks or 5 half lives, whichever is shorter, prior to initiation of study treatment
  2. Active autoimmune disease or a history of severe autoimmune disease or syndrome
  3. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
  4. Inability to comply with study and follow-up procedures.
  5. Pregnancy, lactation, or breastfeeding women.
  6. Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 3 months, unstable arrhythmias, or unstable angina.
  7. Known clinically significant liver disease,
  8. Major surgical procedure within 28 days prior to initiation of study treatment or anticipation of need for a major surgical procedure during the course of the study.
  9. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03119428


Locations
Layout table for location information
United States, Arizona
Scottsdale
Scottsdale, Arizona, United States, 85258
United States, North Carolina
Durham
Durham, North Carolina, United States, 27710
United States, Oklahoma
Oklahoma
Oklahoma City, Oklahoma, United States, 73104
United States, Tennessee
Nashville
Nashville, Tennessee, United States, 37203
United States, Utah
Salt Lake City
Salt Lake City, Utah, United States, 84112
Sponsors and Collaborators
OncoMed Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Study Director: John Lewicki, PhD Mereo BioPharma
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: OncoMed Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03119428    
Other Study ID Numbers: 313M32-001
First Posted: April 18, 2017    Key Record Dates
Last Update Posted: August 11, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplastic Processes
Neoplasms
Pathologic Processes
 Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents